Lyell Immunopharma, INC

Lyell Immunopharma, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of Class II directors and the ratification of its independent auditor.

Lyell Immunopharma reported Q4 and full year 2025 financial results, highlighting significant clinical progress in its CAR T-cell therapy pipeline and an extended cash runway.

Lyell Immunopharma presented promising clinical and translational data for its CAR T-cell therapy ronde-cel in large B-cell lymphoma at the ASH Annual Meeting.

Lyell Immunopharma, Inc. announced amendments to its bylaws, effective immediately, modernizing stockholder proposal procedures and clarifying voting standards.

Lyell Immunopharma announced its third quarter 2025 financial results and significant progress in its CAR T-cell therapy pipeline, including new RMAT designations and clinical trial initiations.

Lyell Immunopharma has acquired exclusive global rights to LYL273, a novel CAR T-cell product candidate for metastatic colorectal cancer, showing promising early clinical results.

Lyell Immunopharma reported progress in its CAR T-cell therapy pipeline, with ongoing clinical trials for ronde-cel and LYL273, alongside a wider net loss for the first quarter of 2026.

Lyell Immunopharma reported a reduced net loss in Q3 2025, driven by lower operating expenses, while advancing its lead CAR T-cell candidates ronde-cel and LYL273 into pivotal trials and further development.

Lyell Immunopharma reported a reduced net loss in Q2 2025, highlighted positive early clinical data for LYL314 in lymphoma, and secured $50 million in new financing.

Lyell Immunopharma announces its Q1 2025 financial results and provides an update on the clinical development of LYL314, its lead CAR T-cell therapy candidate.

Lyell Immunopharma's Q3 2024 report details ongoing clinical trials, a recent acquisition, and a strategic pipeline prioritization.

Lyell Immunopharma's Q2 2024 report details ongoing clinical trials, financial results, and strategic updates, including progress in their cell therapy programs.

Lyell Immunopharma's 2024 10-K filing highlights the company's progress in advancing its CAR T-cell therapy pipeline, including plans for pivotal trials of IMPT-314 and continued development of novel technologies for solid tumors.

Lyell Immunopharma's 2023 annual report details ongoing clinical trials for LYL797 and LYL845, progress in preclinical development of LYL119, and a strategic focus on T-cell reprogramming technologies.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 27, 2026.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 27, 2026.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 17, 2026.

Innovative Cellular Therapeutics Holdings Ltd reported changes in beneficial ownership of Lyell Immunopharma, Inc. common stock on July 16, 2026.

Innovative Cellular Therapeutics Holdings Ltd. reports a transfer of 76,000 common shares as broker commission related to a license agreement, reducing its beneficial ownership.

Innovative Cellular Therapeutics Holdings Ltd, a director and 10% owner of Lyell Immunopharma, Inc., reported a transaction involving the transfer of 66,500 common shares.

Lyell Immunopharma is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and potentially improve stock marketability.

Lyell Immunopharma, Inc. has filed a definitive proxy statement with the SEC.

Lyell Immunopharma's 2024 Annual Meeting of Stockholders will be held virtually on June 14, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and conduct an advisory vote on executive compensation.

Innovative Cellular Therapeutics Holdings Limited has increased its beneficial ownership in Lyell Immunopharma, Inc. to 12.3% following the achievement of a development milestone.

ARCH Venture Partners and affiliated entities have reported a 13.9% beneficial ownership stake in Lyell Immunopharma, Inc.

MWG Caph Ltd and Milky Way Investments Group Ltd report a combined 4.3% stake in Lyell Immunopharma, Inc. as of March 31, 2026.

Explore Investments LLC and Jeffrey P. Bezos have filed a Schedule 13G reporting a 6.6% beneficial ownership stake in Lyell Immunopharma, Inc.

Euler Fund, L.P., along with its general partner Euler Managers Limited and indirect owner Antonis Indianos, has disclosed beneficial ownership of 1,426,528 shares, representing 6.71% of Lyell Immunopharma, Inc.'s common stock.

ARCH Venture Funds and associated individuals collectively report a 13.0% beneficial ownership in Lyell Immunopharma, Inc. common stock.